TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01233102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conserved Therapy
Description: Conserved Therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic artery infusion or Intravenous infusion
Description: Patients with liver cirrhosis will be randomly divided into three groups. Umbilical cord MSCs will be infused to patients using interventional method via hepatic artery for one group. The catheter will be inserted to proper hepatic artery. After the catheter placement confirmed by angiography, umbilical cord MSCs will be infused slowly in 20-30 minutes. Umbilical cord MSCs will be infused intravenously slowly for 30-60 minutes in the intravenous infusion group. The control group will receive conserved therapy.
Study: NCT03431558

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucon-D 99.4% (Placebo)
Description: This group will be given 100mg Glucon-D (99.4% glucose) placebo which will be similar in shape, color to the bLF.
Study: NCT01024855

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RevitaLens OcuTec MPS (Investigational MPS) and Opti-Free RepleniSH MPS (control)
Description: multi-purpose lens care solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RevitaLens OcuTec MPS (Investigational MPS) and Opti-Free RepleniSH MPS (control)
Description: multi-purpose lens care solution
Study: NCT01782937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4827
Description: 140 mg (dosage may be increased to 210 mg in case of insufficient efficacy)
Study: NCT00253838

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration HA stem
Description: The Restoration hip stem, is made from titanium alloy, a different type of metal that has a roughened surfacing and allows for a hydroxylapatite (HA) coating to be applied to the entire length of the stem.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Solution stem
Description: The Solution stem is made from Cobalt Chrome, a type of metal, and does not have a hydroxylapatite (HA) coating.
Study: NCT00003953

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each 2 week course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMF regimen
Description: Stratum I and II: receive cyclophosphamide, methotrexate, and fluorouracil (CMF) for 4 courses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel IV over 1 hour on days 43, 57, and 71.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Doxorubicin IV on days 1, 15, and 29.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Patients with positive estrogen or progesterone receptors receive oral tamoxifen daily for 5 years.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation
Description: Stratum III:may receive high dose chemotherapy with stem cell support

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical procedure
Description: Fourteen to 21 days following preoperative chemotherapy, patients undergo a radical, modified radical, or breast sparing surgery plus axillary lymph node dissection.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiotherapy is administered 5 days a week for 5.5 weeks.
Study: NCT04057105

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active High-definition Transcranial Direct Current Stimulation (HD-tDCS)
Description: Stimulation sessions will be conducted once a day on 10 weekdays over a period of 2-3 weeks. Anodal HD-tDCS will be delivered either in Active or Sham mode (as per the randomized order) in a 4x1 ring configuration (center electrode being Anode and the surrounding 4 electrodes being cathodes) over the affected motor area.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MusicGlove
Description: Both groups will undergo MusicGlove video-game based hand exercises.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MusicGlove
Description: Both groups will undergo MusicGlove video-game based hand exercises.
Study: NCT00743951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1 Patient decision aid
Description: Patients will receive:~i)patient education booklet ii) a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.~iii) a personal decision form is an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.~iv) Referral to the surgeon with a standardized report of their clinical findings plus decisional data (knowledge, values, preference).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 Usual care
Description: Patient will be given i) education booklet from local hospital which is a standardized teaching booklet given to all patients describing preparation for surgery, recovery after surgery, discharge plans.~ii) Referral to the surgeon with a standardized report of their clinical findings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 Usual care
Description: Patient will be given i) education booklet from local hospital which is a standardized teaching booklet given to all patients describing preparation for surgery, recovery after surgery, discharge plans.~ii) Referral to the surgeon with a standardized report of their clinical findings.
Study: NCT03145987

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitis vinifera extract

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00803816

Intervention type: DRUG
Group type: OTHER
Intervention: everolimus
Description: everolimus 1.0 - 2.5mg oral daily dosage
Study: NCT02043847

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow Irradiation
Description: Subjects in this trial will receive total marrow irradiation 3Gy per day for up to four days and as little as one day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)
Description: Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous transplant
Description: Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with autologous stem cell rescue

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow Irradiation
Description: Subjects in this trial will receive total marrow irradiation 6Gy per day for up to four days and as little as one day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)
Description: Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC \> 1000/mm\^3 over period of 3 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous transplant
Description: Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with autologous stem cell rescue

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow Irradiation
Description: Subjects in this trial will receive total marrow irradiation 9Gy per day for up to four days and as little as one day
Study: NCT03289364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Penguin Cold Caps
Description: Patients will wear Penguin Cold Cap scalp cooling device prior to each chemotherapy administration, during administration, and for four hours following administration.
Study: NCT03247803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: air-Q® SP
Description: air-Q SP placement for airway maintenance,

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Williams Airway Intubator (WA)
Description: WA is placed in subject's oropharynx. If the vocal cords are not in view at the end of the WA, the operator may ask an assistant to perform an airway maneuver (e.g., jaw thrust, anterior jaw lift, or lingual traction) to attempt to bring the vocal cords into view
Study: NCT02155153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar Free Chewing Gum
Description: 'Extra' sugar free gum will be used as an intervention. Patients will be required to chew a gum for 30 min at intervals of 6 hours for first 48 hours post operatively or until they pass flatus.
Study: NCT01394094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gum chewing
Description: Gum chewing(30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in the addition to conventional postoperative feeding schedule
Study: NCT03029364

Intervention type: BEHAVIORAL
Intervention: Study Protocol
Description: Participants will complete three study protocols 7 - 28 days apart which includes:~* 3 x main trial days (max. 150 mins) involving body composition analysis, indirect calorimetry, a blood sample, optional muscle and / or adipose tissue biopsies and a maximal cardiorespiratory fitness test.~* 2 x lifestyle monitoring periods (physical activity and diet) for the prior 7 days before each main trial day.~* Maintenance of habitual habits, dietary and physical activity behaviour patterns~We are observing biological / health parameters in a group of individuals who will be assessed under resting and exercising conditions. The current study does not involve an intervention.
Study: NCT02694653

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mL of normal saline IV given 30 minutes prior to elective c/section incision vs acetaminophen 1000 mg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000 mg acetaminophen in 100 mL normal saline IV given 30 minutes prior to elective c/section incision vs placebo
Study: NCT03772860

Intervention type: OTHER
Intervention: Pain stimulation
Description: Pain will be simulated with an electric shock 25 mlAMP over the median nerve

Intervention type: OTHER
Intervention: Pain stimulation
Description: Pain will be simulated with an electric shock 25 mlAMP over the median nerve

Intervention type: OTHER
Intervention: Pain stimulation
Description: Pain will be simulated with an electric shock 25 mlAMP over the median nerve

Intervention type: OTHER
Intervention: Pain stimulation
Description: Pain will be simulated with an electric shock 25 mlAMP over the median nerve

Intervention type: OTHER
Intervention: Visual stimulation
Description: Visual stimulation will be performed by a flicker of light on a computer screen at 15 Hrz for 0.3 seconds

Intervention type: OTHER
Intervention: Visual stimulation
Description: Visual stimulation will be performed by a flicker of light on a computer screen at 15 Hrz for 0.3 seconds

Intervention type: OTHER
Intervention: Visual stimulation
Description: Visual stimulation will be performed by a flicker of light on a computer screen at 15 Hrz for 0.3 seconds

Intervention type: OTHER
Intervention: Visual stimulation
Description: Visual stimulation will be performed by a flicker of light on a computer screen at 15 Hrz for 0.3 seconds

Intervention type: OTHER
Intervention: Auditory stimulation
Description: Auditory stimulation will be delivered through headphones with a sound at 500 Hrz at 85 decibels for 0.3 seconds

Intervention type: OTHER
Intervention: Auditory stimulation
Description: Auditory stimulation will be delivered through headphones with a sound at 500 Hrz at 85 decibels for 0.3 seconds

Intervention type: OTHER
Intervention: Auditory stimulation
Description: Auditory stimulation will be delivered through headphones with a sound at 500 Hrz at 85 decibels for 0.3 seconds

Intervention type: OTHER
Intervention: Auditory stimulation
Description: Auditory stimulation will be delivered through headphones with a sound at 500 Hrz at 85 decibels for 0.3 seconds

Intervention type: OTHER
Intervention: Mental stress
Description: A mathematical challenge will be displayed on a computer screen that must be quickly solved

Intervention type: OTHER
Intervention: Mental stress
Description: A mathematical challenge will be displayed on a computer screen that must be quickly solved

Intervention type: OTHER
Intervention: Mental stress
Description: A mathematical challenge will be displayed on a computer screen that must be quickly solved

Intervention type: OTHER
Intervention: Mental stress
Description: A mathematical challenge will be displayed on a computer screen that must be quickly solved
Study: NCT00582283

Intervention type: DRUG
Group type: OTHER
Intervention: I124-NM404
Description: I-124-NM404
Study: NCT02530567

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention
Description: All patients performing the biopsy will have an MRI to carry out the necessary measures.
Study: NCT01643603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Patients receive dasatinib PO every day (QD) for 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT05631288

Intervention type: GENETIC
Intervention: Sampe collection
Description: Unstimulated crevicular fluid samples are collected using two sized 35 paper cones per subject, both used in the sampling process. The DNA is extracted from the samples through multiplex PCR at the Egas Moniz Applied Microbiology Laboratory (LMAEM).

Intervention type: GENETIC
Intervention: Sampe collection
Description: Unstimulated crevicular fluid samples are collected using two sized 35 paper cones per subject, both used in the sampling process. The DNA is extracted from the samples through multiplex PCR at the Egas Moniz Applied Microbiology Laboratory (LMAEM).
Study: NCT03487003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rocuronium
Description: After standard anesthetic monitoring (non-invasive blood pressure monitor, pulse oximetry, 3-lead echocardiography), patients are inhaled with sevoflurane. When the patients asleep, 0.3 mg/kg rocuronium is administered. After 2 min, flexible laryngeal mask airway (fLMA) is inserted using standard method. The fLMA is inflated with air to 40 cmH2O using manometry. The oropharyngeal leak pressure (OLP) was determined by the method described by Lopez-Gil and colleagues.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline
Description: After standard anesthetic monitoring (non-invasive blood pressure monitor, pulse oximetry, 3-lead echocardiography), patients are inhaled with sevoflurane. When the patients asleep, 0.3 mg/kg saline is administered. After 2 min, flexible laryngeal mask airway (fLMA) is inserted using standard method. The fLMA is inflated with air to 40 cmH2O using manometry. The oropharyngeal leak pressure (OLP) was determined by the method described by Lopez-Gil and colleagues
Study: NCT06373562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypoxia
Description: The athletes were living in hypoxic rooms, which could simulate a selected altitude above sea level.
Study: NCT03250377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Pharmaceutical form: Film-coated tablet~* Concentration: 25 mg and 50 mg~* Route of administration: Oral use
Study: NCT03838250

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellgram™ (Bone marrow-derived MSCs)
Description: Approximately 15 to 30 mL of bone marrow is aspirated from the posterior iliac crest of patients under local anesthesia. Approximately 30 days (±7 days) after BM aspiration, the participant will return to the study center for admission and for the infusion Cellgram™ (Bone marrow-derived MSCs).
Study: NCT03370367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-cis retinoic acid
Description: Taken daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01272180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.
Description: Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus OMV.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.
Description: Two injections of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
Description: One injection of saline solution placebo and one of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.
Description: Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus a quarter dose of OMV.
Study: NCT05342831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological Nutrition Technique
Description: Biological nutrition technique woman trying Biological feeding technique was applied after each breastfeeding. Breastfeeding self-efficacy and breastfeeding success were assessed at regular intervals.
Study: NCT00676559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efalizumab
Description: Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efalizumab
Description: Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
Study: NCT00850772

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Early post-operative enteral feeding
Description: During primary surgical treatment an enteral feeding tube will be inserted through the patient's nose into their small bowel. Enteral feeding will commence 4 hours following return to ward from surgery. Feeding will start at a rate of 40 ml/hr for the first 24 hours, and then increased to goal weight. Goal will be calculated by 125 kiloJoules/kilogram adjusted body weight.
Study: NCT01109706

Intervention type: OTHER
Intervention: biological parameters dosage
Description: 200 patients will be enrolled in the study (n=100 patients under statin treatment, n=100 patients without statin).~After checking inclusion and non-inclusion criteria and obtaining informed consent from the patients. The SYNTAX score will be calculated and will allow to determine coronary analysis will be done at J1 and J4 (glucose, HbA1C, lipids, ApoA1, ApoB, sterols, plasmatic bile acids, insulinemia, creatinin clearance, hepatic function panel, CRPus and PCSK9 level assessment).~Then, a sub-group of 30 patients will have supplementary blood analysis at 1 and 6 months after their admission, during their usual follow-up.

Intervention type: OTHER
Intervention: biological parameters dosage
Description: 200 patients will be enrolled in the study (n=100 patients under statin treatment, n=100 patients without statin).~After checking inclusion and non-inclusion criteria and obtaining informed consent from the patients. The SYNTAX score will be calculated and will allow to determine coronary analysis will be done at J1 and J4 (glucose, HbA1C, lipids, ApoA1, ApoB, sterols, plasmatic bile acids, insulinemia, creatinin clearance, hepatic function panel, CRPus and PCSK9 level assessment).~Then, a sub-group of 30 patients will have supplementary blood analysis at 1 and 6 months after their admission, during their usual follow-up.
Study: NCT02162875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel
Description: Six different treatment strategies with praziquantel
Study: NCT01640743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus + Methylprednisolone
Description: Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (1.5 mg/Kg/die, beginning 1 hour before transplantation) and 1 mg/Kg/die during the following 3 days.~Maintenance therapy:~Tacrolimus dosage will be 0.2 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus + Everolimus + Methylprednisolone
Description: Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (2.5 mg/Kg/die, beginning 1 hour before transplant) and Mycophenolate mofetil (1000 mg) and no immunosuppressive therapy for the following 3 days (WOFIE hypothesis), and for day 4-5-6 thymoglobulins (1.0 mg/Kg/die).~Maintenance therapy:~Tacrolimus dosage will be 0.1 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels
Study: NCT03574545

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ianalumab
Description: Human monoclonal antibody (mAb) of type IgG1/κ binding to B-cell activating-receptor (BAFF-R)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ianalumab
Description: Human monoclonal antibody (mAb) of type IgG1/κ binding to B-cell activating-receptor (BAFF-R)
Study: NCT00629304

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will have face to face visits at 3 and 6 months and no PDA-FIT system. Patients will record glycemia on paper support.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VISITS + PDA-FIT system
Description: patients will have face to face visits at 3 and 6 months + PDA-FIT system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PDA-FIT System + telephone follow-up
Description: patients will received PDA-FIT system + a telephone follow up (12 phone calls) and a face to face visit at 6 months